CareDx Inc
$ 19.41
2.97%
04 Dec - close price
- Market Cap 1,003,328,000 USD
- Current Price $ 19.41
- High / Low $ 19.80 / 18.63
- Stock P/E 14.73
- Book Value 6.05
- EPS 1.28
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE 0.24 %
- 52 Week High 25.95
- 52 Week Low 10.96
About
CareDx, Inc. is a leading biotechnology company based in South San Francisco, California, focused on revolutionizing transplant medicine through its innovative diagnostic solutions. With a specialty in advanced surveillance tools, the company enhances transplant outcomes and promotes personalized care for organ transplant recipients. Their robust portfolio includes a range of cutting-edge tests and software platforms that aim to improve the quality of life for patients and caregivers alike, solidifying CareDx's position as a vital player in the evolving healthcare landscape.
Analyst Target Price
$22.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-04 | 2024-07-31 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-10 | 2023-02-27 |
| Reported EPS | 0.28 | 0.1 | 0.1 | 0.18 | 0.14 | 0.25 | -0.03 | -0.17 | -0.18 | -0.18 | -0.11 | -0.07 |
| Estimated EPS | -0.08 | -0.1 | 0.0683 | 0.1475 | 0.01 | -0.14 | -0.21 | -0.27 | -0.4 | -0.31 | -0.11 | -0.09 |
| Surprise | 0.36 | 0.2 | 0.0317 | 0.0325 | 0.13 | 0.39 | 0.18 | 0.1 | 0.22 | 0.13 | 0 | 0.02 |
| Surprise Percentage | 450% | 200% | 46.4129% | 22.0339% | 1300% | 278.5714% | 85.7143% | 37.037% | 55% | 41.9355% | 0% | 22.2222% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDNA
2025-10-15 02:32:00
The Third Circuit has denied medical testing company CareDx's appeal for a full panel review regarding the reinstatement of a $45 million jury award. This decision relates to a false advertisement case, indicating a potential finality in the circuit court's stance on the verdict.
2025-10-15 02:32:00
The Third Circuit has denied medical testing company CareDx's request for a full panel review to reinstate a $45 million jury award in a false advertising lawsuit. This case involved genetic testing technology and was brought against their rival, Natera. The decision was made on Tuesday, October 14, 2025.
2025-10-15 02:32:00
The Third Circuit has declined CareDx's request for a full panel review regarding the reinstatement of a $45 million jury award in a false advertisement lawsuit. This decision pertains to a case where medical testing company CareDx was previously awarded damages.
2025-10-12 05:11:23
CareDx (NASDAQ:CDNA) has been downgraded to a "Sell" rating by Wall Street Zen. The company's stock experienced a 2.3% drop, and institutional investors have been actively trading shares, with some increasing stakes while others made new purchases. CareDx specializes in diagnostic solutions for transplant patients, offering products like AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung.
2025-08-22 14:12:00
CareDx Inc. has agreed to a $20.25 million securities class action settlement for consumers who purchased common stock between May 1, 2020, and Nov. 3, 2022, and suffered damages. The lawsuit alleged the company made misrepresentations and omissions about compliance with laws and revenue disclosures, causing artificial inflation of its stock price. Eligible class members can claim a pro rata cash payment, with a claim deadline of Nov. 12, 2025.
2025-08-06 11:30:08
CareDx, Inc. (Nasdaq: CDNA) has appointed Nathan Smith as its new Chief Financial Officer, leveraging his 14 years of experience in molecular diagnostics. His role will focus on leading financial and accounting initiatives aligned with the company's strategic growth plan. Nathan replaces Abhishek Jain, who is retiring but will provide consulting support for a smooth transition.
